Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.84 USD
Change Today -0.05 / -0.23%
Volume 41.3K
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 10:33 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

dynavax technologies corp (DVAX) Snapshot

Open
$21.91
Previous Close
$21.89
Day High
$22.22
Day Low
$21.72
52 Week High
03/24/15 - $26.89
52 Week Low
07/28/14 - $13.10
Market Cap
639.7M
Average Volume 10 Days
400.9K
EPS TTM
$-3.81
Shares Outstanding
29.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYNAVAX TECHNOLOGIES CORP (DVAX)

dynavax technologies corp (DVAX) Related Businessweek News

No Related Businessweek News Found

dynavax technologies corp (DVAX) Details

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company’s product pipeline includes HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; SD-101, a CpG TLR9 agonist for the treatment of cancer immunotherapy that is in Phase I/II clinical trials; AZD1419, a drug candidate for the treatment of asthma, which has completed Phase I trial; DV1179, a TLR7/9 inhibitor that is in Phase I clinical trial for autoimmune or inflammatory conditions; and DV230-Nanoparticle, a second generation adjuvant that is in preclinical studies. It has a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease; and strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

197 Employees
Last Reported Date: 03/5/15
Founded in 1996

dynavax technologies corp (DVAX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $515.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $354.2K
Senior Vice President of Operations and Quali...
Total Annual Compensation: $309.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $440.0K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $358.8K
Compensation as of Fiscal Year 2014.

dynavax technologies corp (DVAX) Key Developments

Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

Merck and Dynavax Technologies Corporation announced they have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies’ pipelines: Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax’s investigational toll-like receptor 9 (TLR9) agonist, SD-101. SD-101, KEYTRUDA, and MK-1966 are immunotherapies designed to enhance the body’s own defenses in fighting cancer. SD-101 is designed to mediate anti-tumor effects by triggering both innate and adaptive immune responses, including the induction of high levels of Type 1 interferon to stimulate recruitment of T-cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. MK-1966 is an investigational anti-IL-10 immunomodulator designed to neutralize the immune-suppressive environment for tumors. The collaboration includes multiple studies that will evaluate: Safety and efficacy of combining SD-101 with KEYTRUDAin patients with advanced melanoma; this Phase 1b/2, multicenter, open-label study is expected to be initiated in the second half of 2015. Safety and efficacy of combining SD-101 with MK-1966 in patients with solid or hematological malignancies; this Phase 1 study is expected to be initiated in the second half of 2015. Under the terms of the agreement, Dynavax will sponsor and fund the SD-101 and KEYTRUDA study. Merck will sponsor and fund the SD-101 and MK-1966 study. The agreements include provisions where the parties may agree to extend either collaboration to include a Phase 3 clinical trial. Additional details of the agreements between Dynavax and Merck, through a subsidiary, were not disclosed.

Dynavax Technologies Corporation Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

Dynavax Technologies Corporation reported unaudited consolidated financial results for the first quarter ended March 31, 2015. The net loss allocable to common stockholders for the quarter ended March 31, 2015 was $26.2 million, or $0.97 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended December 31, 2014 was $22.3 million, or $0.85 per basic and diluted share. For the quarter, the company reported total revenues of $0.627 million, loss from operations of $26.452 million compared to the revenues of $3.498 million, loss from operations of $13.967 million for the same quarter year ago.

Dynavax Technologies Corporation, Annual General Meeting, May 27, 2015

Dynavax Technologies Corporation, Annual General Meeting, May 27, 2015., at 10:00 Pacific Standard Time. Location: Company's executive offices at 2929 Seventh Street, Suite 100. Agenda: To elect nominees for class III directors to hold office until the 2018 annual meeting of stockholders or until their respective successors are duly elected and qualified; to amend and restate the company 2011 equity incentive plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 2,250,000, and to approve the award limits and other terms applicable to awards intended to qualify as performance-based compensation for purposes of section 162(m) of the internal revenue code; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2015; and to conduct any other business properly brought before the meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $21.84 USD -0.05

DVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $27.30 USD +0.12
Genocea Biosciences Inc $10.78 USD -0.06
GenVec Inc $2.35 USD +0.06
Inovio Pharmaceuticals Inc $8.60 USD +0.175
ZIOPHARM Oncology Inc $9.71 USD +0.024
View Industry Companies
 

Industry Analysis

DVAX

Industry Average

Valuation DVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 74.8x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 67.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit www.dynavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.